Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will continue to evaluate bortezomib in follicular lymphoma subgroups as part of its larger development program for the first-in-class proteasome inhibitor.
You may also be interested in...
Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance
Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.
Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance
Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.
Onyx Files Carfilzomib For Accelerated Approval With Two Phase III Trials Ongoing
FDA has expressed preference for having multiple confirmatory trials in the works to support an accelerated approval application.